Dr Antoine Hollebecque

Spécialité

Oncologue médical, expert colon, estomac, foie et pancréas

Hôpital

Gustave Roussy (Villejuif)

Derniers articles

• Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer. (7 juin 2025)
• Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers. (3 juin 2025)
• Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials. (1 juin 2025)
• Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [The Lancet Regional Health - Europe, volume 50, March 2025, 101170]. (30 avr. 2025)
• Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma. (1 janv. 2025)